EFM
FATE icon

E Fund Management’s Fate Therapeutics FATE Stock Holding History

E Fund Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-339,994
Closed -$561K – 413
2024
Q4 		$561K Sell
339,994
-13,777
-4% -$34.7K 0.03% 209
2024
Q3 		$1.24M Sell
353,771
-1,454
-0.4% -$5.66K 0.06% 126
2024
Q2 		$1.17M Buy
355,225
+320,745
+930% +$1.4M 0.06% 113
2024
Q1 		$253K Buy
+34,480
New +$213K 0.02% 298
2023
Q3 		– Sell
-51,350
Closed -$244K – 302
2023
Q2 		$244K Sell
51,350
-27,787
-35% -$153K 0.02% 252
2023
Q1 		$451K Buy
79,137
+56,781
+254% +$343K 0.03% 135
2022
Q4 		$226K Buy
22,356
+5,404
+32% +$101K 0.02% 281
2022
Q3 		$380K Sell
16,952
-5,151
-23% -$149K 0.04% 194
2022
Q2 		$548K Buy
22,103
+14,107
+176% +$389K 0.05% 129
2022
Q1 		$310K Buy
7,996
+4,468
+127% +$173K 0.01% 187
2021
Q4 		$206K Buy
+3,528
New +$200K 0.01% 257

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

E Fund Management's FATE Position: Q1 2025 in Review

E Fund Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 339,994 shares — an estimated $561K sold.

E Fund Management first reported a position in FATE in Q4 2021 and held it in 11 quarters. The position peaked at $1.24M in Q3 2024. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • E Fund Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • E Fund Management sold 339,994 Fate Therapeutics shares in Q1 2025, an estimated $561K.
  • E Fund Management first reported a position in Fate Therapeutics in Q4 2021 and held it in 11 quarters.
  • E Fund Management's Fate Therapeutics position peaked at $1.24M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on E Fund Management's 13F filing for Q1 2025, filed 13 May 2025.